Results of a study investigating pembrolizumab combined with vorinostat for treatment of relapsed Hodgkin lymphoma.
Home / Resource Library / Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockade